226330 — Syntekabio Balance Sheet
0.000.00%
- KR₩109bn
- KR₩105bn
- KR₩121m
Annual balance sheet for Syntekabio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 41,091 | 52,709 | 35,342 | 19,668 | 12,066 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 362 | 248 | 281 | 231 | 59.9 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 41,536 | 58,193 | 37,497 | 21,980 | 12,565 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,582 | 9,054 | 17,475 | 30,461 | 30,672 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 44,778 | 67,879 | 55,689 | 52,917 | 43,715 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,037 | 1,888 | 22,254 | 19,398 | 16,301 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,238 | 40,252 | 24,228 | 21,688 | 18,772 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 41,540 | 27,627 | 31,461 | 31,228 | 24,943 |
Total Liabilities & Shareholders' Equity | 44,778 | 67,879 | 55,689 | 52,917 | 43,715 |
Total Common Shares Outstanding |